{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:22:14Z","timestamp":1793024534539,"version":"4.5.0"},"reference-count":32,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2025.2854","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T06:57:55Z","timestamp":1745391475000},"page":"1-6","source":"Crossref","is-referenced-by-count":3,"title":["Perioperative nintedanib for lung resection in patients with idiopathic pulmonary fibrosis"],"prefix":"10.3892","volume":"22","author":[{"given":"Ryusuke","family":"Sumiya","sequence":"first","affiliation":[{"name":"Department of General Thoracic Surgery, Juntendo University Nerima Hospital, Tokyo 177\u20118521, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamitsu","family":"Banno","sequence":"additional","affiliation":[{"name":"Department of General Thoracic Surgery, Juntendo University Nerima Hospital, Tokyo 177\u20118521, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyasu","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of General Thoracic Surgery, Juntendo University Nerima Hospital, Tokyo 177\u20118521, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunki","family":"Hirayama","sequence":"additional","affiliation":[{"name":"Department of General Thoracic Surgery, Juntendo University Nerima Hospital, Tokyo 177\u20118521, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo 113\u20110033, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"issue":"2837","key":"key20250513105908_b1-MCO-22-6-02854","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16162837","article-title":"Lung cancer and interstitial lung diseases","volume":"16","author":"Drakopanagiotakis","year":"2024","journal-title":"Cancers (Basel)"},{"key":"key20250513105908_b2-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1164\/ajrccm.161.1.9906062","article-title":"Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study","volume":"161","author":"Hubbard","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"key20250513105908_b3-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1136\/thx.2009.121962","article-title":"Cryptogenic fibrosing alveolitis and lung cancer: The BTS study","volume":"65","author":"Harris","year":"2010","journal-title":"Thorax"},{"key":"key20250513105908_b4-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s00595-014-1071-5","article-title":"Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis","volume":"45","author":"Iwata","year":"2015","journal-title":"Surg Today"},{"key":"key20250513105908_b5-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.athoracsur.2011.06.055","article-title":"Survival after surgery for pathologic stage IA non-small cell lung cancer associated with idiopathic pulmonary fibrosis","volume":"92","author":"Saito","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"key20250513105908_b6-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.jtcvs.2008.07.016","article-title":"Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis?","volume":"136","author":"Watanabe","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"key":"key20250513105908_b7-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1159\/000342046","article-title":"Efficacy of chemotherapy for advanced nonsmall cell lung cancer with idiopathic pulmonary fibrosis","volume":"85","author":"Watanabe","year":"2013","journal-title":"Respiration"},{"key":"key20250513105908_b8-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2021.12.018","article-title":"Survival after surgery for clinical stage I non-small-cell lung cancer with interstitial pneumonia","volume":"165","author":"Fukui","year":"2022","journal-title":"Lung Cancer"},{"key":"key20250513105908_b9-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.jtcvs.2013.09.050","article-title":"Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer","volume":"147","author":"Sato","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"key":"key20250513105908_b10-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00595-020-01978-9","article-title":"Perioperative pirfenidone treatment as prophylaxis against acute exacerbation of idiopathic pulmonary fibrosis: A single-center analysis","volume":"50","author":"Sekihara","year":"2020","journal-title":"Surg Today"},{"key":"key20250513105908_b11-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): A double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"key20250513105908_b12-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"},{"key":"key20250513105908_b13-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"key20250513105908_b14-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"key20250513105908_b15-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N Engl J Med"},{"key":"key20250513105908_b16-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"key20250513105908_b17-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1164\/rccm.200404-571OC","article-title":"Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"171","author":"Azuma","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"key20250513105908_b18-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1183\/09031936.00005209","article-title":"Pirfenidone in idiopathic pulmonary fibrosis","volume":"35","author":"Taniguchi","year":"2010","journal-title":"Eur Respir J"},{"key":"key20250513105908_b19-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"issue":"e1600","key":"key20250513105908_b20-MCO-22-6-02854","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001600","article-title":"Double-blind randomized trial of pirfenidone in chinese idiopathic pulmonary fibrosis patients","volume":"94","author":"Huang","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"key20250513105908_b21-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"issue":"90","key":"key20250513105908_b22-MCO-22-6-02854","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-016-0398-4","article-title":"A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan oncology group 6711 L (PEOPLE Study)","volume":"17","author":"Iwata","year":"2016","journal-title":"Respir Res"},{"key":"key20250513105908_b23-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report","volume":"194","author":"Collard","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"key20250513105908_b24-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"key20250513105908_b25-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/CE.S82905","article-title":"Nintedanib: Evidence for its therapeutic potential in idiopathic pulmonary fibrosis","volume":"10","author":"Inomata","year":"2015","journal-title":"Core Evid"},{"key":"key20250513105908_b26-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res"},{"key":"key20250513105908_b27-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"key20250513105908_b28-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","article-title":"Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small cell lung cancer (NEJ026): Interim analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"20","author":"Saito","year":"2019","journal-title":"Lancet Oncol"},{"key":"key20250513105908_b29-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00280-014-2590-x","article-title":"The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease","volume":"74","author":"Shimizu","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"80","key":"key20250513105908_b30-MCO-22-6-02854","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-018-2002-4","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: Lessons learned from acute respiratory distress syndrome?","volume":"22","author":"Marchioni","year":"2018","journal-title":"Crit Care"},{"key":"key20250513105908_b31-MCO-22-6-02854","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/resp.14352","article-title":"Antifibrotics and lung transplantation: A Spanish multicentre case-controlled study","volume":"27","author":"Cuesta","year":"2022","journal-title":"Respirology"},{"issue":"e2307360","key":"key20250513105908_b32-MCO-22-6-02854","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202307360","article-title":"AuNPs\/CNC nanocomposite with a \u2018Dual Dispersion\u2019 effect for LDI-TOF MS analysis of intact proteins in NSCLC serum exosomes","volume":"11","author":"Shan","year":"2024","journal-title":"Adv Sci (Weinh)"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T07:59:14Z","timestamp":1747123154000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2025.2854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,4,23]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2025.2854","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]}}}